INSPIRE UNDER SEC INVESTIGATION

Inspire Pharmaceuticals said early Wednesday that it is being formally probed by the Securities and Exchange Commission for trading events surrounding its announcement of clinical data for its drug diquafosol tetrasodium on February 9. In a release, the company said it believes the probe stems from trading of the companies securities around February 9, when it reported disappointing data for the drug from a Phase III clinical trial. Inspire's stock plunged more than 40% on the news.

MarketWatch (http://www.marketwatch.com/news/story.asp?guid=%7BCAB9F646-6F56-4406-A9B3-8B0854F9A8E3%7D&siteid=google)